13TH INTERNATIONAL CONFERENCE OF CONTEMPORARY ONCOLOGY

 

ONLINE, 20.04.2022 - 23.04.2022

NOTICE! LECTURE TIMES ARE SET ACCORDING TO GMT+2 TIME ZONE (Warsaw, Poland)
Use the timezone converter to easily convert to your time GO TO CONVERTER
World Clock
 
20
kwietnia
Wednesday
11:45 - 14:10
SESSION 1. Predisposition and cancer risk
Chair:
  Jan Lubiński
Szczecin, PL
 
  Jacek Gronwald
Szczecin, PL
 
11:45 - 12:10
Lowering cancer risk in patients with inherited predisposition by optimizing dietary parameters
  Jan Lubiński
Szczecin, PL
 
12:10 - 12:35
Hereditary factors of ovarian cancers
  Jacek Gronwald
Szczecin, PL
 
12:35 - 13:00
Clinics of breast cancers in carriers of CHEK2 mutations
 
13:00 - 13:25
Lead blood level as marker of cancer risk
Marcin Lener
  Marcin Lener
Szczecin, PL
 
13:25 - 13:50
Serum selenium level as marker of survival in patients with malignant melanoma
  Tadeusz Dębniak
Szczecin, PL
 
13:50 - 14:10
DISCUSSION
14:10 - 14:20
BREAK
14:20 - 17:05
SESSION 2. Tumor microenvironment
Chair:
Claudine Kieda
  Claudine Kieda
Orleans, FR / Warszawa, PL
 
Viktor Umansky
  Viktor Umansky
Heidelberg, GER
 
14:20 - 14:45
Tumor oximetry and hypoxia modification in preclinical model
Martyna Elas
  Martyna Elas
Kraków, PL
 
14:45 - 15:10
Adjuvant therapy based on tumor microenvironment conditions
Claudine Kieda
  Claudine Kieda
Orleans, FR / Warszawa, PL
 
15:10 - 15:35
Evaluation of microheterogeneity of microenvironment in daily pathological practice
  Andrzej Marszałek
Poznań, PL
 
15:35 - 16:00
Intratumor heterogeneity assessed by mass spectrometry imaging and cancer prognosis
Piotr Widłak
  Piotr Widłak
Gdańsk, PL
 
16:00 - 16:25
Immunosuppression in tumor microenvironment and its targeting
Viktor Umansky
  Viktor Umansky
Heidelberg, GER
 
16:25 - 17:05
DISCUSSION
17:05 - 17:15
BREAK
17:15 - 19:30
SESSION 3. Immunomodulation
Chair:
Salem Chouaib
  Salem Chouaib
Paris, FR
 
17:15 - 18:10
Reprograming responsiveness of tolerogenic CD8+ T cells by oncolytic virotherapy with CXCR4-antagonist is associated with reversing M2 macrophage polarization
18:10 - 18:45
The turbulent hypoxia-anti-tumor immune response relationship
Salem Chouaib
  Salem Chouaib
Paris, FR
 
18:45 - 19:10
Dendritic cell-targeting therapies of cancer
Paweł Kalinski
  Paweł Kalinski
Buffalo, USA
 
19:10 - 19:30
DISCUSSION
19:30 - 19:40
BREAK
19:40 - 19:50
WELCOME ADDRESS
Andrzej Mackiewicz
  Andrzej Mackiewicz
Poznań, PL
 
19:50 - 20:20
Keynote lecture:
Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells
Pravin Sehgal
  Pravin Sehgal
New York, USA
 
20:20 - 20:50
Keynote lecture:
Myeloma 2022 - Main Challenges and Path Forward
Andrzej Jakubowiak
 


21
kwietnia
Thursday
12:15 - 15:05
SESSION 4. Cancer targeting
Chair:
Hanna Rokita
  Hanna Rokita
Kraków, PL
 
Lidia Gil
  Lidia Gil
Poznań, PL
 
12:15 - 12:40
Proteomic profile of melanoma cell-drived small extracellular vesicles correlate of melanoma progression
 
12:40 - 13:05
Cancer stemness and proteogenomics for target identification
  Maciej Wiznerowicz
Poznań, PL
 
13:05 - 13:30
Targeting GD2 ganglioside in neuroblastoma induces PHLDA1 and modulates cell metabolism
Hanna Rokita
  Hanna Rokita
Kraków, PL
 
13:30 - 13:55
Organotropic Approach to Novel Anticancer Therapies
Waldemar Priebe
  Waldemar Priebe
Houston, USA
 
13:55 - 14:20
CAR T-cell therapy in ALL - where are we in 2022
Lidia Gil
  Lidia Gil
Poznań, PL
 
14:20 - 14:45
Boosting GvL by direct exposure of donor lymphocytes to leukemic cells at relapse employing intra-bone route
Andrzej Lange
  Andrzej Lange
Wrocław, PL
 
14:45 - 15:05
DISCUSSION
15:05 - 15:15
BREAK
15:15 - 17:10
SESSION 5. Mechanisms and markers of cancer I
Chair:
Theresa Whiteside
  Theresa Whiteside
Pittsburg, USA
 
15:15 - 15:40
Blocking Key Steps in Inflammation and Cancer
15:40 - 16:05
Small Extracellular Vesicles (sEVs) in cancer plasma as contributors to liquid tumor biopsy
Theresa Whiteside
  Theresa Whiteside
Pittsburg, USA
 
16:05 - 16:30
Circulating Tumour Cells (CTC): do we have a new risk assessment marker in the progression of oligometastatic disease?
16:30 - 16:55
Diagnostic and predictive value of circulating melanoma cells in patients treated with immunotherapy
Łukasz Galus, Karolina Buszka, Anna Szoszkiewicz, Mariusz Kaczmarek, Michał Nowicki, Jacek Mackiewicz, Joanna Budna-Tukan
Paula Kamińska
 
16:55 - 17:10
DISCUSSION
17:10 - 17:20
BREAK
17:20 - 20:10
SESSION 6. Mechanisms and markers of cancer II
Chair:
17:20 - 17:45
Breast cancer- dissimilarity between male and female tumors.
  Piotr Czapiewski
Dessau-Roßlau, GER
 
17:45 - 18:10
Methylation profile of ovarian tumors
  Laura Szafron
Warszawa, PL
 
18:10 - 18:35
RNA editing in cancer
Małgorzata Kurkowiak
  Małgorzata Kurkowiak
Gdańsk, PL
 
18:35 - 19:00
IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
Tomasz K. Wojdacz
 
19:00 - 19:25
Profile of peripheral blood NK cells in melanoma patients treated with immune checkpoint inhibitors
Katarzyna Tomela, Łukasz Galus, Bernadeta Pietrzak,  Marcin Schmidt, Jacek Mackiewicz, Andrzej Mackiewicz
 
19:25 - 19:50
Gut microbial and metabolic profiles associated with response to treatment with PD1/PD-L1 blockade therapy in metastatic melanoma
Artur Szwengiel, Bernadeta Pietrzak, Katarzyna Tomela, Łukasz Galus, Agnieszka Olejnik-Schmidt, Mariusz Kaczmarek, Jacek Mackiewicz, Andrzej Mackiewicz
Marcin Schmidt
 
19:50 - 20:10
DISCUSSION


22
kwietnia
Friday
13:30 - 15:20
SESSION 7: Postępy w leczeniu chorych na raka jelita grubego
Advances in the treatment of patients with colorectal cancer
Chair:
  Barbara Radecka
Opole, PL
 
  Piotr Milecki
Poznań, PL
 
13:30 - 13:50
Zalety i wady laparoskopii u chorych na raka jelita grubego
Advantages and disadvantages of laparoscopy in patients with colorectal cancer
13:50 - 14:10
Postępy w leczeniu chirurgicznym przerzutów do wątroby
Advances in the surgical treatment of liver metastases
Dawid Murawa
  Dawid Murawa
Poznań, PL
 
14:10 - 14:30
Postępy w radioterapii u chorych na raka odbytnicy
Advances in radiotherapy in patients with rectal cancer
  Piotr Milecki
Poznań, PL
 
14:30 - 14:50
Postępy w terapii celowanej u chorych na raka jelita grubego
Advances in targeted therapy in patients with colorectal cancer
Rafał Stec
  Rafał Stec
Warszawa, PL
 
14:50 - 15:10
Wykład sponsorowany / Sponsored lecture
Miejsce immunoterapii w leczeniu chorych na nowotwory jelita grubego MSI-H
The place of immunotherapy in the treatment of patients (MSI-H) colorectal cancer
  Barbara Radecka
Opole, PL
 
15:10 - 15:20
DISCUSSION
15:20 - 15:30
BREAK
15:30 - 17:45
SESSION 8: Postępy w leczeniu chorych na czerniaka
Advances in the treatment of patients with melanoma
Chair:
Piotr Rutkowski
 
Jacek Mackiewicz
 
15:30 - 15:50
Nowe trendy w diagnostyce czerniaków skóry
New trends in the diagnosis of skin melanomas
  Jacek Calik
Wrocław, PL
 
15:50 - 16:10
Wykład pod patronatem
Jak poprawić skuteczność leczenia u chorych na czerniaka
How to improve the effectiveness of treatment in patients with melanoma
Jacek Mackiewicz
 
16:10 - 16:30
Co nowego, a co bez zmian w chirurgicznym leczeniu chorych na czerniaka?
What's new, and what's the same in the surgical treatment of melanoma patients?
16:30 - 16:50
Wykład sponsorowany / Sponsored lecture
Leczenie okołooperacyjne u chorych na czerniaka
Perioperative treatment in patients with melanoma
Piotr Rutkowski
 
16:50 - 17:10
Wykład sponsorowany / Sponsored lecture
Kryteria doboru immunoterapii u chorych na uogólnionego czerniaka
Criteria for selecting immunotherapy in patients with metastatic melanoma
17:10 - 17:30
Miejsce terapii celowanej u chorych na uogólnionego czerniaka
The place of targeted therapy in patients with metastatic melanoma
Anna Czarnecka
  Anna Czarnecka
Warszawa, PL
 
17:30 - 17:45
DISCUSSION
17:45 - 17:55
BREAK
17:55 - 19:45
SESSION 9:
Targeted therapy in lympho- and myeloproliferative neoplasms: new concepts and new expectations
Chair:
Krzysztof Lewandowski
  Krzysztof Lewandowski
Poznań, PL
 
17:55 - 18:20

STAT and JAK gene mutations in lympho- and myeloproliferative disorders
Krzysztof Lewandowski
  Krzysztof Lewandowski
Poznań, PL
 
18:20 - 18:45

JAK-STAT pathways inhibitors in the treatment of myeloproliferative neoplasms
  Marta Sobas
Wrocław, PL
 
18:45 - 19:10

Novel targeted therapies of T cell lymphomas
19:10 - 19:35

1-line treatment of CLL/SLL: Targeted Therapy or Chemoimmunotherapy?
Krzysztof Jamroziak
  Krzysztof Jamroziak
Warszawa, PL
 
19:35 - 19:45
DISCUSSION


23
kwietnia
Saturday
09:00 - 10:55
SESSION 10: Postępy w leczeniu chorych na raka płuca
Advances in the treatment of patients with lung cancer
Chair:
Rodryg Ramlau
  Rodryg Ramlau
Poznań, PL
 
  Tadeusz Orłowski
Warszawa, PL
 
09:00 - 09:20
Postępy w leczeniu chirurgicznym u chorych na raka płuca
Advances in surgical treatment in lung cancer patients
  Tadeusz Orłowski
Warszawa, PL
 
09:20 - 09:40
Postępy w leczeniu chorych na miejscowo zaawansowanego niedrobnokomórkowego raka płuca
Advances in the treatment of patients with locally advanced non-small cell lung cancer
  Anna Wrona
Gdańsk, PL
 
09:40 - 10:00
Wykład pod patronatem
Pierwsza linia leczenia u chorych na niedrobnokomórkowego raka płuca
The first line of treatment in patients with non-small cell lung cancer
Adam Płużański
  Adam Płużański
Warszawa, PL
 
10:00 - 10:20
Wykład sponsorowany / Sponsored lecture
Immunoterapia skojarzona - w leczeniu chorych na niedrobnokomórkowego raka płuca
Combined immunotherapy - in the treatment of patients with non-small cell lung cancer
Rodryg Ramlau
  Rodryg Ramlau
Poznań, PL
 
10:20 - 10:40
Nowości w leczeniu chorych na drobnokomórkowego raka płuca
New solutions in the treatment of patients with small cell lung cancer
Katarzyna Stencel
  Katarzyna Stencel
Poznań, PL
 
10:40 - 10:55
DISCUSSION
10:55 - 11:05
BREAK
11:05 - 12:45
SESSION 11. Postępy w terapii systemowej u chorych na nowotwory złośliwe
Advances in the treatment of cancer patients
Chair:
  Piotr Tomczak
Poznań, PL
 
  Wojciech Rogowski
Słupsk, PL
 
11:05 - 11:25
Wykład pod patronatem
Postępy w leczeniu systemowym u chorych na nowotwory głowy i szyi
Advances in systemic therapy in patients with head and neck cancer
Izabela Łasińska
  Izabela Łasińska
Poznań, PL
 
11:25 - 11:45
Wykład sponsorowany / Sponsored lecture
Postępy w leczeniu systemowym u chorych na zaawansowanego raka nerki
Advances in systemic treatment in patients with advanced kidney cancer
  Piotr Tomczak
Poznań, PL
 
11:45 - 12:05
Wykład sponsorowany / Sponsored lecture
Postępy w immunoterapii górnego odcinka przewodu pokarmowego
Advances in immunotherapy of the upper gastrointestinal tract
  Tomasz Kubiatowski
Olsztyn, PL
 
12:05 - 12:25
Leczenie podtrzymujące u chorych na raka pęcherza moczowego
Maintenance treatment in patients with bladder cancer
  Wojciech Rogowski
Słupsk, PL
 
12:25 - 12:45
Leczenie kolczystokomórkowego (płaskonabłonkowego) raka skóry w oparciu o przypadki kliniczne
Treatment of squamous cell skin cancer based on clinical cases
  Hanna Koseła-Paterczyk
Warszawa, PL
 
12:45 - 13:00
DISCUSSION
13:00 - 13:10
BREAK
13:10 - 14:15
SESSION 12. Presentations selected from Abstracts
Chair:
Andrzej Mackiewicz
  Andrzej Mackiewicz
Poznań, PL
 
Jacek Mackiewicz
 
13:10 - 13:20
Biological heterogeneity of primary cancer associated fibroblasts isolated from breast cancer tissue
Marika Musielak
Poznań, PL
13:20 - 13:30
A rare case of a neurological adverse event of immune checkpoint inhibitors - LIMBIC ENCEPHALITIS
Weronika Radecka
Opole, PL
13:30 - 13:40
miR-27b-5p: a short non-coding RNA with diagnostic potential in head and neck squamous cell carcinoma
Joanna Kozłowska-Masłoń
Poznań, PL
13:40 - 13:50
Chloride intracellular channels in head and neck squamous cell carcinoma
Bartosz Wojtera
Poznań, PL
13:50 - 14:30
DISCUSSION
CLOSING THE CONFERENCE